Extra heart recruits for Mesoblast
Friday, 27 February, 2009
A good safety report has allowed recruitment to proceed of a further group of patients for a Phase II trial of Angioblast’s Revascor universal adult stem cell product.
Angioblast, the US-based sister company of Melbourne’s Mesoblast, is conducting a Phase II trial of Revascor in patients with congestive heart failure.
No adverse effects were recorded in the first 20 patients on a low dose of the product. Recruitment will now begin for another 20-person group to receive a higher dose.
The allogeneic stem cell product is being developed to reverse congestive heart failure by rebuilding blood vessels and heart muscle.
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
